PBC – how do you make the case for biologicals?
The National Institute for Health and Clinical Excellence (NICE) technology appraisal guidance 103, Etanercept and efalizumab for the treatment of adults with psoriasis, was issued in July 2006. It recommends that etanercept (Enbrel®, Wyeth, UK) be used within its licensed indications in patients with severe plaque psoriasis when other treatments have not worked or the patient is intolerant to or has a contraindication to these treatments. A definition is given in the guidance of severe psoriasis but no definition is provided for what is meant by ‘intolerant to’.
Dermatology in practice 2006; 14(3): 14–16
To continue reading this article, please sign in or register.